TheraRadar
Clinical-Stage Companies / Protagonist

Protagonist

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 10/7/2025

13
Total Trials
2
Phase 3
7
Phase 2
2
Recruiting
98
Score

Pipeline by Phase

Phase 3
2
Phase 2
7
Phase 1
4

Therapeutic Focus

Polycythemia Vera Healthy Volunteers β-thalassemia Ineffective Erythropoiesis Healthy Volunteer

Clinical Trials (13)

NCT05210790 Phase 3 ACTIVE NOT RECRUITING

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

Started: 4/11/2022

NCT06033586 Phase 3 ACTIVE NOT RECRUITING

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

Started: 1/22/2024

NCT02895100 Phase 2 TERMINATED

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

Started: 12/1/2016

NCT04202965 Phase 2 COMPLETED

PTG-300 in Subjects With Hereditary Hemochromatosis

Started: 3/19/2020

NCT04057040 Phase 2 COMPLETED

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

Started: 10/1/2019

NCT04767802 Phase 2 COMPLETED

PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

Started: 2/2/2021

NCT04504383 Phase 2 COMPLETED

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Started: 8/5/2020

NCT03802201 Phase 2 COMPLETED

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

Started: 12/19/2018

NCT04054921 Phase 2 COMPLETED

Safety Study for Beta Thalassemia Subjects on PTG-300

Started: 5/10/2019

NCT07153146 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

Started: 10/7/2025

NCT04819620 Phase 1 COMPLETED

Pharmacokinetics of PN-232 in Healthy Volunteers

Started: 5/13/2021

NCT04621630 Phase 1 COMPLETED

Pharmacokinetics of PN-235 in Healthy Volunteers

Started: 11/12/2020

NCT04516382 Phase 1 COMPLETED

Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers

Started: 9/14/2020

Drug Candidates

PN-881 Oral Solution PN-881 Oral Tablet PTG-100 PTG-300 Rusfertide Open-label rusfertide PN-943 PN-232 PN-235
Activity Status: Slowing
Last Trial Started: 10/7/2025
Last Trial Ended: 7/29/2026
Trials (12 months): 0
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.